Developer docs
API playgroundTry for free, no card

Search company profiles

Prota Therapeutics

Full company profile

uuid0000jx9

Namestring
Prota Therapeutics
Legal namestring
Prota Therapeutics Pty Ltd
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Prota Therapeutics is a late clinical-stage Australian biotechnology company developing PRT120, a proprietary oral immunotherapy (OIT) for the treatment of peanut allergy. The company was founded in 2016 in Melbourne, Australia, and the PRT120 platform is exclusively licensed from the Murdoch Children's Research Institute (MCRI), where it was developed over more than 20 years of research led by Scientific Founder Professor Mimi Tang. The therapy is designed to redirect the peanut-specific immune response from a Th2 allergic phenotype toward tolerance, aiming for sustained unresponsiveness (remission) rather than temporary desensitization, with the goal of allowing patients to consume peanut freely after treatment is discontinued. Clinical evidence includes a 51% remission rate in the PPOIT-003 study, greater than 85% reduction in peanut-specific IgE antibody levels persisting to 12 months post-treatment, and durable tolerance effects confirmed four years after treatment ended in the PPOIT-003LT follow-up.

PRT120 is investigational and not approved for marketing in any region, and the company currently generates no product revenue. Prota's business model is a one-time license-style prescription pharmaceutical model: upon regulatory approval, the product would be sold through standard pharmaceutical distribution channels (wholesale distributors, specialty pharmacies) and prescribed by allergists, immunologists, and pediatricians to patients (primarily children and adults) with diagnosed peanut allergy. The company has raised approximately US$36 million cumulatively, including a US$21 million round led by SPRIM Global Investments in January 2024 earmarked for Phase 3 clinical trials and commercialization preparation. An add-on Digital Allergy Management App accompanies the core therapeutic asset as part of a broader patient-care offering.

Prota's end customers are patients with peanut allergy, approximately 1 in 50 people in the US, and the healthcare providers who treat them. Peanut allergy is the most common cause of life-threatening food-related anaphylaxis and is typically lifelong, with current standard of care limited to avoidance and emergency treatment. Prota addresses this unmet need by pursuing clinical remission rather than lifelong maintenance desensitization. The company is headquartered in Camberwell, Melbourne, and is privately held, with board representation from lead investors OneVentures and SPRIM Global Investments and an experienced leadership team spanning clinical immunology, regulatory affairs, clinical operations, and biotech finance.

Short descriptiontext

Prota Therapeutics is a late clinical-stage Australian biotech developing PRT120, an investigational oral immunotherapy for peanut allergy that aims to achieve durable remission rather than lifelong desensitization. The product is licensed from Murdoch Children's Research Institute and is preparing for Phase 3 clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peanut allergy treatment, oral immunotherapy, food allergy therapeutics, allergen immunotherapy, biopharmaceutical development
Industry1 code
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Allergy Immunotherapy Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Prota Therapeutics' food allergy treatments are investigational and not yet approved for marketing. Once PRT120 receives regulatory approval, the company will generate revenue through prescription pharmaceutical product sales targeting patients with peanut allergy.

protatherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Prota Therapeutics is developing PRT120, a proprietary oral immunotherapy for peanut allergy that aims to achieve sustained unresponsiveness (remission) rather than temporary desensitization by redirecting the peanut-specific immune response from allergy toward tolerance. The treatment is investigational and not yet approved for marketing in any region, with a pivotal Phase 3 clinical trial planned. Prota's technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, where it was developed over more than 20 years of research led by Professor Mimi Tang.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 51% peanut allergy remission rate in clinical trials - first company to validate significant quality of life improvements compared with standard care
+2 more records
Product overview1 text field

Prota Therapeutics is a late clinical-stage Australian biotech company developing a single proprietary oral immunotherapy product, PRT120, for peanut allergy treatment. The company's technology is based on over two decades of research from Professor Mimi Tang's team at Murdoch Children's Research Institute. PRT120 is a phase-3 ready peanut allergy oral immunotherapy that aims to achieve remission (sustained unresponsiveness) rather than temporary desensitization, allowing patients to freely consume peanut in their diet without ongoing maintenance therapy. The company also developed a digital allergy management app to support patient care alongside the core therapeutic product.

Product and service1 record
1PRT120
CategoryOral Immunotherapy / Biopharmaceutical
Description

PRT120 is Prota Therapeutics' phase-3 ready proprietary oral immunotherapy treatment for peanut allergy. It is designed to redirect the peanut-specific immune response from the allergy (Th2) pathway towards tolerance, aiming to achieve sustained unresponsiveness (remission) rather than just temporary desensitization. The product is intended to enable patients to consume peanut freely without ongoing maintenance therapy. The product is investigational and is not approved for marketing in any region.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Prota's proprietary technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, developed over 20+ years of research led by Professor Mimi Tang. This licensing arrangement provides Prota with rights to the PPOIT (Probiotic and Peanut Oral Immunotherapy) technology platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of Palforzia (peanut oral immunotherapy), the first FDA-approved peanut allergy OIT. Most directly comparable to Prota in target indication, modality (oral immunotherapy), and patient population; later acquired by Nestlé Health Science. Provides a direct read on regulatory pathway, commercial uptake, and competitive positioning for peanut OIT.

TypeDirect peer
Description

French biotech developing Viaskin Peanut, an epicutaneous immunotherapy patch for peanut allergy in children. Competes in the same peanut allergy space with a different delivery modality (patch vs oral), making it a close comparator for market opportunity and regulatory benchmarks.

3Alladapt Immunotherapeutics
TypeEmerging player
Description

US clinical-stage biotech developing ADP101, a multi-food allergen oral immunotherapy targeting peanut plus other common allergens. Comparable in approach (oral immunotherapy) but broader in allergen coverage; useful comp for clinical and regulatory trajectory in food OIT.

TypeEmerging player
Description

US early-stage biotech developing engineered allergen-specific IgG antibodies for peanut and other food allergies. Represents an emerging next-generation approach (passive immunization) competing with active OIT like PRT120 in the same indication.

TypeDirect peer
Description

UK-based specialty immunotherapy company with a peanut allergy vaccine (VLP Peanut) in clinical development and a broader allergy immunotherapy portfolio. Comparable in modality (allergen-specific immunotherapy) and regulatory pathway; longer commercial track record in allergy.

TypeBroad incumbent
Description

Danish global leader in allergy immunotherapy with a broad portfolio of subcutaneous and sublingual immunotherapy products across respiratory and food allergens. Serves as a broad incumbent benchmark for commercial infrastructure, payer access, and allergy market dynamics relevant to PRT120's future commercialization.

TypeBroad incumbent
Description

Global specialty biopharmaceutical company focused on allergen immunotherapy, now the parent of Aimmune (Palforzia). Provides both broad-incumbent scale comparison and a relevant reference for commercializing peanut OIT after acquiring the most direct competitor to Prota.

TypeBroad incumbent
Description

Global pharmaceutical company whose Dupixent (dupilumab) is being investigated in food allergy (including peanut) and represents a potential competing biologic modality in the same indication. Relevant as both a competitive threat and a potential partnering/acquirer for differentiated food allergy assets like PRT120.

9Moonlight Therapeutics
TypeEmerging player
Description

US early-stage biotech developing dissolvable microneedle patches for peanut allergy immunotherapy. Competes in the same indication with a different delivery technology, providing a useful comparator for safety, adherence, and pediatric patient experience versus PRT120 oral therapy.

TypeBroad incumbent
Description

Co-developer with Sanofi of Dupilumab (Dupixent) which has food allergy programs including in peanut allergy. Relevant broad incumbent for biologic competition in food allergy and as a potential strategic partner or acquirer of differentiated allergy assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prota Therapeutics

Allergy Immunotherapy Biopharmaceuticalsprotatherapeutics.com

Prota Therapeutics is a late clinical-stage Australian biotech developing PRT120, an investigational oral immunotherapy for peanut allergy that aims to achieve durable remission rather than lifelong desensitization. The product is licensed from Murdoch Children's Research Institute and is preparing for Phase 3 clinical trials.

What Prota Therapeutics does

Prota Therapeutics is a late clinical-stage Australian biotechnology company developing PRT120, a proprietary oral immunotherapy (OIT) for the treatment of peanut allergy. The company was founded in 2016 in Melbourne, Australia, and the PRT120 platform is exclusively licensed from the Murdoch Children's Research Institute (MCRI), where it was developed over more than 20 years of research led by Scientific Founder Professor Mimi Tang. The therapy is designed to redirect the peanut-specific immune response from a Th2 allergic phenotype toward tolerance, aiming for sustained unresponsiveness (remission) rather than temporary desensitization, with the goal of allowing patients to consume peanut freely after treatment is discontinued. Clinical evidence includes a 51% remission rate in the PPOIT-003 study, greater than 85% reduction in peanut-specific IgE antibody levels persisting to 12 months post-treatment, and durable tolerance effects confirmed four years after treatment ended in the PPOIT-003LT follow-up.

PRT120 is investigational and not approved for marketing in any region, and the company currently generates no product revenue. Prota's business model is a one-time license-style prescription pharmaceutical model: upon regulatory approval, the product would be sold through standard pharmaceutical distribution channels (wholesale distributors, specialty pharmacies) and prescribed by allergists, immunologists, and pediatricians to patients (primarily children and adults) with diagnosed peanut allergy. The company has raised approximately US$36 million cumulatively, including a US$21 million round led by SPRIM Global Investments in January 2024 earmarked for Phase 3 clinical trials and commercialization preparation. An add-on Digital Allergy Management App accompanies the core therapeutic asset as part of a broader patient-care offering.

Prota's end customers are patients with peanut allergy, approximately 1 in 50 people in the US, and the healthcare providers who treat them. Peanut allergy is the most common cause of life-threatening food-related anaphylaxis and is typically lifelong, with current standard of care limited to avoidance and emergency treatment. Prota addresses this unmet need by pursuing clinical remission rather than lifelong maintenance desensitization. The company is headquartered in Camberwell, Melbourne, and is privately held, with board representation from lead investors OneVentures and SPRIM Global Investments and an experienced leadership team spanning clinical immunology, regulatory affairs, clinical operations, and biotech finance.

Prota Therapeutics firmographics

Firmographics
Name
Prota Therapeutics
Legal name
Prota Therapeutics Pty Ltd
Website
https://protatherapeutics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Prota Therapeutics is a late clinical-stage Australian biotech developing PRT120, an investigational oral immunotherapy for peanut allergy that aims to achieve durable remission rather than lifelong desensitization. The product is licensed from Murdoch Children's Research Institute and is preparing for Phase 3 clinical trials.
Ownership category
akta.pro rank

Prota Therapeutics industry classification

Industry
Product category
Allergy Immunotherapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Peanut allergy treatment
  • Oral immunotherapy
  • Food allergy therapeutics
  • Allergen immunotherapy
  • Biopharmaceutical development

Where Prota Therapeutics is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Prota Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Prota Therapeutics' food allergy treatments are investigational and not yet approved for marketing. Once PRT120 receives regulatory approval, the company will generate revenue through prescription pharmaceutical product sales targeting patients with peanut allergy.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Prota Therapeutics product offering

Product offering

Core offering

Prota Therapeutics is developing PRT120, a proprietary oral immunotherapy for peanut allergy that aims to achieve sustained unresponsiveness (remission) rather than temporary desensitization by redirecting the peanut-specific immune response from allergy toward tolerance. The treatment is investigational and not yet approved for marketing in any region, with a pivotal Phase 3 clinical trial planned. Prota's technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, where it was developed over more than 20 years of research led by Professor Mimi Tang.

Product overview

Prota Therapeutics is a late clinical-stage Australian biotech company developing a single proprietary oral immunotherapy product, PRT120, for peanut allergy treatment. The company's technology is based on over two decades of research from Professor Mimi Tang's team at Murdoch Children's Research Institute. PRT120 is a phase-3 ready peanut allergy oral immunotherapy that aims to achieve remission (sustained unresponsiveness) rather than temporary desensitization, allowing patients to freely consume peanut in their diet without ongoing maintenance therapy. The company also developed a digital allergy management app to support patient care alongside the core therapeutic product.

Differentiator

Problem solved

Functional benefit

Products and services

  • PRT120 PRT120 is Prota Therapeutics' phase-3 ready proprietary oral immunotherapy treatment for peanut allergy. It is designed to redirect the peanut-specific immune response from the allergy (Th2) pathway towards tolerance, aiming to achieve sustained unresponsiveness (remission) rather than just temporary desensitization. The product is intended to enable patients to consume peanut freely without ongoing maintenance therapy. The product is investigational and is not approved for marketing in any region.

Quantifiable outcome

  • 51% peanut allergy remission rate in clinical trials - first company to validate significant quality of life improvements compared with standard care
  • +2 more outcomes

Companies that use Prota Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Prota Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Prota Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Murdoch Children's Research Institute (MCRI)coreTechnology or IntegrationProta's proprietary technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, developed over 20+ years of research led by Professor Mimi Tang. This licensing arrangement provides Prota with rights to the PPOIT (Probiotic and Peanut Oral Immunotherapy) technology platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Prota Therapeutics competitors and assessment

Company assessment

Direct peers

  • Aimmune Therapeutics: Developer of Palforzia (peanut oral immunotherapy), the first FDA-approved peanut allergy OIT. Most directly comparable to Prota in target indication, modality (oral immunotherapy), and patient population; later acquired by Nestlé Health Science. Provides a direct read on regulatory pathway, commercial uptake, and competitive positioning for peanut OIT.
  • DBV Technologies: French biotech developing Viaskin Peanut, an epicutaneous immunotherapy patch for peanut allergy in children. Competes in the same peanut allergy space with a different delivery modality (patch vs oral), making it a close comparator for market opportunity and regulatory benchmarks.
  • Allergy Therapeutics: UK-based specialty immunotherapy company with a peanut allergy vaccine (VLP Peanut) in clinical development and a broader allergy immunotherapy portfolio. Comparable in modality (allergen-specific immunotherapy) and regulatory pathway; longer commercial track record in allergy.

Emerging players

  • Alladapt Immunotherapeutics: US clinical-stage biotech developing ADP101, a multi-food allergen oral immunotherapy targeting peanut plus other common allergens. Comparable in approach (oral immunotherapy) but broader in allergen coverage; useful comp for clinical and regulatory trajectory in food OIT.
  • IgGenix: US early-stage biotech developing engineered allergen-specific IgG antibodies for peanut and other food allergies. Represents an emerging next-generation approach (passive immunization) competing with active OIT like PRT120 in the same indication.
  • Moonlight Therapeutics: US early-stage biotech developing dissolvable microneedle patches for peanut allergy immunotherapy. Competes in the same indication with a different delivery technology, providing a useful comparator for safety, adherence, and pediatric patient experience versus PRT120 oral therapy.

Broad incumbents

  • ALK-Abelló: Danish global leader in allergy immunotherapy with a broad portfolio of subcutaneous and sublingual immunotherapy products across respiratory and food allergens. Serves as a broad incumbent benchmark for commercial infrastructure, payer access, and allergy market dynamics relevant to PRT120's future commercialization.
  • Stallergenes Greer: Global specialty biopharmaceutical company focused on allergen immunotherapy, now the parent of Aimmune (Palforzia). Provides both broad-incumbent scale comparison and a relevant reference for commercializing peanut OIT after acquiring the most direct competitor to Prota.
  • Sanofi (Dupixent): Global pharmaceutical company whose Dupixent (dupilumab) is being investigated in food allergy (including peanut) and represents a potential competing biologic modality in the same indication. Relevant as both a competitive threat and a potential partnering/acquirer for differentiated food allergy assets like PRT120.
  • Regeneron Pharmaceuticals: Co-developer with Sanofi of Dupilumab (Dupixent) which has food allergy programs including in peanut allergy. Relevant broad incumbent for biologic competition in food allergy and as a potential strategic partner or acquirer of differentiated allergy assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Prota Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prota Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Prota Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prota Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prota Therapeutics

What does Prota Therapeutics do?

Prota Therapeutics is developing PRT120, a proprietary oral immunotherapy for peanut allergy that aims to achieve sustained unresponsiveness (remission) rather than temporary desensitization by redirecting the peanut-specific immune response from allergy toward tolerance. The treatment is investigational and not yet approved for marketing in any region, with a pivotal Phase 3 clinical trial planned. Prota's technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, where it was developed over more than 20 years of research led by Professor Mimi Tang.

Is Prota Therapeutics a public or private company?

Prota Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prota Therapeutics founded?

Prota Therapeutics was founded in 2016. It employs 1 to 10 people.

Where is Prota Therapeutics based?

Prota Therapeutics is headquartered in Melbourne, Australia, in the Oceania region.

How does Prota Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Prota Therapeutics's main competitors?

Direct peers on record are Aimmune Therapeutics, DBV Technologies and Allergy Therapeutics. Emerging players are Alladapt Immunotherapeutics, IgGenix and Moonlight Therapeutics. Broad incumbents are ALK-Abelló, Stallergenes Greer, Sanofi (Dupixent) and Regeneron Pharmaceuticals.

Does Prota Therapeutics have an API?

No public API is recorded for Prota Therapeutics.

What industry is Prota Therapeutics in?

Prota Therapeutics's product category is Allergy Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireProta Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick MachadoProta Therapeutics appointed Patrick Machado as chair of its board, effective immediately. He brings over 30 years of biotech experience, including co-founding Medivation. The appointment follows $21 million in funding and supports the company's Phase 3 trial of its peanut allergy treatment.PR Newswire APACProta Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024Prota Therapeutics CEO Professor Mimi Tang received the Distinguished Leadership Award at the 2024 BioMelbourne Network Women in Leadership Awards for her contributions to food allergy research. Her work includes leading the development of novel immunotherapies, notably securing US$21 million for a Phase 3 clinical trial of the PRT120 oral therapy for peanut allergy. Additionally, she is recognized for creating the AllergyPal mobile app and her extensive academic record in immunology.FinSMEsProta Therapeutics Raises US $21M in Equity and Debt FinancingProta Therapeutics, a biotechnology company based in Melbourne, raised US$21M in equity and debt funding to accelerate its Phase 3 clinical investigation of PRT120 oral therapy for peanut allergy. The funding round was led by SPRIM Global Investments, indicating strong investor confidence in Prota's novel oral immunotherapy treatments. Established in 2016, Prota Therapeutics aims to commercialize these innovative therapies for food allergies, building on over 15 years of research.PR NewswireProta Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric PatientsProta Therapeutics announced that its Phase 2b clinical trial results, published in The Lancet Child & Adolescent Health, demonstrated that 51% of paediatric patients achieved sustained clinical remission from peanut allergy after 18 months of treatment with its PRT120 oral immunotherapy. To support further Phase 3 clinical investigation and global commercialization of the drug, the company has initiated a new round of capital raising.FinSMEsProta Therapeutics Raises $10M in Series B FundingProta Therapeutics, an Australian developer of a peanut allergy treatment for children, raised $10M in Series B funding from OneVentures Healthcare Fund III. The funds will advance its clinical trial program, including completing recruitment of a multicentre study and preparing regulatory documentation.